28th Sep 2026 10:33
28 September 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Director/PDMR Shareholding
Coiled Therapeutics (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, advises that Stephen West, Non-Executive Director, has today purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
Number of Ordinary Shares Acquired | Average Price Paid per Ordinary Share | Total Consideration Paid (including charges) | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
531,743 | 7.52 pence | £40,016.77 | 2,700,368 | 0.63% |
Regulatory Information
This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").
-ENDS-
Enquiries:
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO)
| Via Burson Buchanan |
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
| +44 (0)20 3470 0470 |
Shore Capital Stockbrokers Limited (Joint Broker) David Coaten / Sophie Collins
| +44 (0)20 7408 4090 |
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino | +61 (0)8 9223 2222 |
| |
Burson Buchanan (Public Relations) | +44 (0)20 7466 5000 |
Henry Harrison Topham / Jamie Hooper / Toto Berger | |
Harbor Access (US Investor Relations) | +1 475 477 9404 |
Matt Kelly / Jonathan Paterson |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in an ongoing Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy focuses on generating evidence in selected tumour types, including ovarian and prostate cancer, to support potential pharmaceutical partnerships. Its broader pipeline includes a STAT-6 siRNA programme for immunology indications.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.
By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.
The Company is currently enrolling patients in dose-escalation cohorts evaluating the new lipid-based softgel formulation of AO-252. Phase I/II dose-expansion cohorts in ovarian and prostate cancer are planned to follow once the optimal dose has been established.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Stephen West | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification /Amendment | Initial | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Coiled Therapeutics plc | |
b) | LEI | 254900P4SISIWOR9RH34 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value
ISIN: GB00BSHRN331 | |
b) | Nature of the transaction | Purchase of 531,743 Ordinary Shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
7.399 pence per share | 270,306 | ||
7.650 pence per share | 261,437 | ||
d | Aggregated information - Aggregated volume - Price |
- 531,743 - 7.52p | |
e) | Date of the transactions | 28 September 2026 | |
f) | Place of the transactions | London Stock Exchange (XLON); AIM | |
Related Shares:
Coiled Thera